Services / endocrinology weight loss
Semaglutide Weight Loss Program in Chicago
Semaglutide is an FDA-approved GLP-1 receptor agonist that has revolutionized medical weight loss. Originally developed for type 2 diabetes, Semaglutide (known by brand names Ozempic and Wegovy) has shown remarkable efficacy for weight management -- with the STEP 1 trial showing an average weight loss of about 15% of body weight at 68 weeks. At Stonewood Health, our medically supervised Semaglutide programs include comprehensive metabolic testing, Dosing set from your labs, nutritional guidance, and ongoing monitoring for safe, sustainable results.
Book a visit
What it helps with
Average weight loss of about 15% of body weight in the STEP 1 trial
Reduces appetite and food cravings
Improves metabolic health markers
Once-weekly injection
Improves blood sugar and A1C levels
Reduces cardiovascular risk factors
Sustainable weight management with lifestyle support
What happens
Initial consultation and health assessment
Comprehensive metabolic and blood panel
BMI, body composition, and baseline measurements
Begin Semaglutide at starting dose with gradual titration
Monthly check-ins with weight and metabolic monitoring
Nutritional counseling and lifestyle support
Ongoing dose management for best results
Who it is for
Semaglutide is ideal for adults with a BMI of 27+ with weight-related conditions, or BMI 30+ seeking medical weight management.
Adults with BMI 30+ (obesity)
Adults with BMI 27+ and weight-related health conditions
Those who haven't achieved lasting results with diet and exercise alone
Patients seeking an FDA-approved, evidence-based solution
Those wanting to reduce metabolic disease risk factors
Questions
Related
Tirzepatide (Mounjaro/Zepbound)
Tirzepatide is the most powerful FDA-approved weight loss medication available today. As a dual …
Obesity Management
Our comprehensive obesity management program combines FDA-approved medications, metabolic testin…
Peptide Therapy
Insulin resistance is a key driver of weight gain, metabolic syndrome, and type 2 diabetes. Our …